Salubris(SZ:002294) Xin Lang Zheng Quan·2025-11-24 01:56Core Viewpoint - The stock of Shenzhen Xinlitai Pharmaceutical Co., Ltd. has shown significant growth this year, with a year-to-date increase of 101.51% as of November 24, 2023, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Xinlitai achieved a revenue of 3.241 billion yuan, representing a year-on-year growth of 8.00%. The net profit attributable to shareholders was 581 million yuan, reflecting a year-on-year increase of 13.93% [2]. - Since its A-share listing, Xinlitai has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 24, 2023, Xinlitai's stock price was 61.32 yuan per share, with a market capitalization of 68.361 billion yuan. The stock experienced a trading volume of 52.4896 million yuan and a turnover rate of 0.08% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on June 17, 2023, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of September 30, 2025, Xinlitai had 25,200 shareholders, an increase of 4.87% from the previous period. The average number of circulating shares per shareholder was 44,249, a decrease of 4.64% [2]. - The top circulating shareholders include China Europe Medical Health Mixed A (holding 27.1792 million shares) and Hong Kong Central Clearing Limited (holding 18.9212 million shares), with both increasing their holdings compared to the previous period [3].